Employer profile
Elastrin Therapeutics
2 certified H-1B filings across 1 fiscal year.
FY2023 filings
2
FY2023 median
$90k
Top role
Senior Scientist Formulation
2 filings
Top state
SC
2 filings
Elastrin Therapeutics has filed 2 certified H-1B Labor Condition Applications over FY2023. In FY2023, its median certified base salary was $90k ($90k–$90k interquartile range). The most-filed role is Senior Scientist Formulation (2 filings).
Year-over-year
How Elastrin Therapeutics hired across H-1B fiscal years. YoY column compares to the prior FY.
| FY | Filings | Median $ | YoY % |
|---|---|---|---|
| FY2023 | 2 | $90k | — |
Top job titles
Most-filed positions, across all years (raw DOL titles).
| Job Title | Filings | Median |
|---|---|---|
| Senior Scientist Formulation | 2 | $90k |
Top worksite states
Where this employer files.
| State | Filings | Median |
|---|---|---|
| SC | 2 | $90k |
Prevailing wage level distribution
DOL Levels I–IV approximate experience tiers (I = entry, IV = fully competent). A heavy Level I/II skew suggests entry-level / contractor-style hiring; a heavy IV skew suggests senior in-house roles.
Lvl I
2100%
Frequently asked questions
- Does Elastrin Therapeutics sponsor H-1B visas?
- Yes. Elastrin Therapeutics has filed 2 certified H-1B Labor Condition Applications (LCAs) over FY2023. An LCA is a required step before an employer files an H-1B petition; a certified LCA does not by itself guarantee an approved visa.
- What is the median H-1B salary at Elastrin Therapeutics?
- In FY2023, the median certified H-1B base salary at Elastrin Therapeutics was $90k, with a 25th–75th percentile range of $90k–$90k. This is the annual base wage stated on the LCA and excludes bonus, equity, and other compensation.
- What jobs does Elastrin Therapeutics hire H-1B workers for?
- Elastrin Therapeutics's most-filed H-1B role is Senior Scientist Formulation (2 filings). Its top worksite state is SC.
- How many H-1B filings did Elastrin Therapeutics submit in FY2023?
- Elastrin Therapeutics had 2 certified H-1B LCA filings in FY2023.